<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple myeloma: Management in resource-limited settings</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple myeloma: Management in resource-limited settings</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple myeloma: Management in resource-limited settings</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vania Hungria, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple myeloma (MM) is a plasma cell neoplasm characterized by clonal plasma cells that produce a monoclonal immunoglobulin. These plasma cells proliferate in the bone marrow and can result in extensive skeletal destruction with osteolytic lesions, osteopenia, and/or pathologic fractures. Additional disease-related complications include hypercalcemia, kidney impairment, anemia, and infections. Treatment directed at the underlying plasma cell clone is required to prevent complications and improve overall survival. </p><p>MM must be distinguished from the premalignant stages of myeloma, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>). In contrast to MM, active treatment is not routinely indicated for patients with MGUS or SMM. </p><p>This topic discusses management of patients with MM in resource-limited settings largely defined as those areas with limited access to <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> analogs, proteasome inhibitors, monoclonal antibodies, and other novel agents that are commonly used in resource-abundant settings. Separate discussions are available regarding diagnosis and management in resource-abundant settings.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">COMMON CHALLENGES IN THE RESOURCE-LIMITED SETTING</span><span class="headingEndMark"> — </span>While major advances in the field of MM have improved the diagnosis, risk stratification, and management of patients in resource-abundant settings, much of the world faces challenges in their broad application. Common themes of these challenges include [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Heterogeneous access to care and disparities between those with private insurance, government-based care, and self pay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delays in diagnosis leading to more patients with advanced, highly symptomatic disease impacting eligibility for different therapies (eg, hematopoietic cell transplantation [HCT]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited access to advanced molecular studies to aid risk stratification and disease monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prohibitive costs of novel therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited staffing and logistical support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limitations in epidemiologic data given the lack of consistent registries. </p><p></p><p>The disparities between public and private care were highlighted in a retrospective study of 148 patients with MM treated in Mexico [<a href="#rid2">2</a>]. Patients in the two groups had a similar age at presentation (mean 59 versus 61 years) and percentage eligible for HCT (62 versus 63 percent). When compared with those treated in private settings, patients treated at public hospitals were more likely to: </p><p class="bulletIndent1"><span class="glyph">●</span>Have advanced disease at diagnosis as illustrated by higher rates of International Staging System (ISS) stage III disease (51 versus 28 percent), kidney impairment (25 versus 13 percent), and hypercalcemia (28 versus 13 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Receive less effective initial treatment as illustrated by increased use of thalidomide-based regimens (91 versus 18 percent), less use of bortezomib-based regimens (4 versus 75 percent), and a lower percentage of transplant-eligible patients undergo transplant (38 versus 84 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Experience inferior outcomes as illustrated by worse progression-free survival (median 23 versus 41 months) and overall survival (median 51 versus 79 months), and higher rates of death within 12 months of diagnosis (13 versus 4 percent). </p><p></p><p>These challenges were further highlighted in a retrospective study of 1103 patients with newly diagnosed MM treated in seven Latin American countries between 2008 and 2015, which reported the following [<a href="#rid4">4</a>]:  </p><p class="bulletIndent1"><span class="glyph">●</span>High rate of end-organ involvement at diagnosis (bone disease 79 percent; anemia 73 percent; kidney disease 27 percent; hypercalcemia 17 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited access to cytogenetics for risk stratification (not available for 80 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low percentage of patients undergoing HCT (34 percent) despite a median age of 61 years. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Common regimens used were <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> based (55 percent), <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> based (29 percent), and chemotherapy (10 percent). Those treated in a non-private setting were more likely to receive thalidomide-based therapy (71 versus 34 percent) and less likely to receive bortezomib (15 versus 54 percent).  </p><p></p><p class="headingAnchor" id="H513191657"><span class="h1">CLINICAL PRESENTATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Patients in resource-limited settings are more likely to have diagnostic delays and more advanced disease at the time of diagnosis [<a href="#rid2">2</a>]. Most patients with MM present with signs or symptoms related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains: </p><p class="bulletIndent1"><span class="glyph">●</span>Common presentations include anemia, bone pain, elevated creatinine or serum protein, fatigue, and hypercalcemia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less common presentations that require urgent evaluation include spinal cord compression, acute kidney failure, severe hypercalcemia, and hyperviscosity. </p><p></p><p>Diagnosis is based on criteria from the International Myeloma Working Group  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>) [<a href="#rid5">5</a>]. An approach to the evaluation of suspected cases may need to be modified based on available resources  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>). The clinical features, laboratory manifestations, diagnosis, and differential diagnosis are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Clinical presentation'</a>.)</p><p>The main conditions to consider in the differential diagnosis for MM include monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, Waldenström macroglobulinemia, solitary plasmacytoma, AL amyloidosis, POEMS syndrome, and metastatic carcinoma  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef67431" href="/z/d/graphic/67431.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H3366782603"><span class="h1">GENERAL MANAGEMENT PRINCIPLES</span></p><p class="headingAnchor" id="H3132892010"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>Patients with MM are not cured with conventional therapy. Treatment alleviates symptoms, reverses cytopenias, and decreases end-organ damage, and it is given with the overall goals of improving quality of life and prolonging overall survival (OS). </p><p>Prior to the development of effective therapies, median OS was less than one year among patients with symptomatic MM [<a href="#rid6">6</a>]. Treatment with <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> improved median OS of such patients to approximately three years [<a href="#rid7">7</a>]. Additional OS improvements came with the transition from two-drug regimens to three-drug or four-drug regimens and the incorporation of additional novel therapies at progression. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p class="headingAnchor" id="H1226260381"><span class="h2">Prevention and management of complications</span><span class="headingEndMark"> — </span>In addition to therapy directed at the malignant clone, the management of most patients with MM includes preventative measures to reduce the incidence of skeletal events, kidney damage, infections, neuropathy, and thrombosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skeletal lesions and bone health</strong> – Osteoclast inhibitors (eg, bisphosphonates) are administered to prevent skeletal events in patients with one or more lesions on skeletal imaging and those with osteopenia  (<a class="graphic graphic_algorithm graphicRef127382" href="/z/d/graphic/127382.html" rel="external">algorithm 2</a>). While <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> is commonly used in patients with kidney impairment in resource-abundant settings, access is limited in resource-limited settings. <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">Zoledronic acid</a> requires dose adjustment for kidney impairment. (See  <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors"</a>.)</p><p></p><p class="bulletIndent1">Skeletal lesions can result in bone pain, pathologic fractures, and spinal cord compression.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pathologic fractures or impending fractures of long bones require stabilization. Vertebral fractures may benefit from kyphoplasty or vertebroplasty. Most pain related to lytic lesions can be controlled with the combination of analgesics and active myeloma therapy. (See  <a class="medical medical_review" href="/z/d/html/132146.html" rel="external">"Management of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spinal cord compression is a clinical emergency and should be suspected in patients with severe back pain, weakness, or paresthesias of the lower extremities, or bladder or bowel dysfunction or incontinence. (See  <a class="medical medical_review" href="/z/d/html/2820.html" rel="external">"Treatment and prognosis of neoplastic epidural spinal cord compression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney impairment</strong> – All patients with MM should take measures to minimize kidney damage (eg, avoid nephrotoxins such as aminoglycosides and nonsteroidal anti-inflammatory drugs [NSAIDs] and maintain adequate hydration). Treatment of kidney impairment is directed at the underlying cause. (See  <a class="medical medical_review" href="/z/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Prophylactic measures used to minimize infection in patients with MM include yearly influenza vaccines; pneumococcal vaccine at the time of diagnosis; and prophylactic antibiotics during the first months of induction chemotherapy. Antiviral and pneumocystis prophylaxis may also be indicated. (See  <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">"Infections in patients with multiple myeloma"</a>.)</p><p></p><p class="bulletIndent1">Patients suspected of having an infection should be treated promptly with empiric antibiotics. (See  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboprophylaxis </strong>– Patients with MM are at increased risk of having comorbidities known to be risk factors for the development of venous thromboembolism (VTE) in the general population. In addition, treatment with immunomodulatory drugs (eg, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>) is associated with high rates of VTE. All patients with MM should have an assessment of their VTE risk so that appropriate prophylaxis may be employed  (<a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathy</strong> – Peripheral neuropathy, often painful, can occur in association with various MM treatments, including <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>. The frequency and severity of peripheral neuropathy with bortezomib can be reduced by adjusting the route (subcutaneous rather than intravenous administration) and frequency (once versus twice weekly) of administration. (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Specific recommendations for bortezomib'</a>.)</p><p></p><p class="bulletIndent1">Peripheral neuropathy is more frequent and severe in those who have previously received neurotoxic therapy and those with pre-existing neuropathy [<a href="#rid8">8</a>]. When neuropathy occurs, it can impair quality of life and ability to perform activities of daily living. Management is discussed separately, including dose modification and/or treatment discontinuation. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Thalidomide and related agents'</a> and  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Bortezomib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercalcemia</strong> – Patients with hypercalcemia may be asymptomatic or present with anorexia, nausea, vomiting, polyuria, polydipsia, constipation, weakness, confusion, or stupor. The treatment of hypercalcemia depends on the calcium level, the rapidity with which it developed, and the patient's symptoms. Emergency treatment with hydration, glucocorticoids, bisphosphonates, and/or hemodialysis/<a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">calcitonin</a> is indicated for symptomatic patients. (See  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p></p><p class="headingAnchor" id="H3292456054"><span class="h1">INITIAL TREATMENT</span><span class="headingEndMark"> — </span>The initial treatment of patients in resource-limited settings is individualized based on access to drugs/modalities and patient comorbidities. There is no standard of care and different experts use different regimens. Our approach is largely influenced by  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Eligibility for and access to autologous hematopoietic cell transplantation (HCT)</p><p class="bulletIndent1"><span class="glyph">●</span>Access to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a></p><p></p><p>Both of these modalities improve overall survival (OS) in patients with MM. </p><p>Unlike in resource-abundant settings, resource-limited settings have limited access to fluorescence in situ hybridization (FISH) for risk stratification. As such, treatment is selected without knowledge of whether the patient has high- or standard-risk MM. As discussed in more detail separately, limited data suggest that proteasome inhibitors such as <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> may abrogate the prognostic impact of at least some high-risk genetic markers making bortezomib-containing therapies an attractive option regardless of risk. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'High-risk myeloma'</a>.)</p><p>All patients are strongly encouraged to participate in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=6650" target="_blank">clinical trials</a>, where available.</p><p class="headingAnchor" id="H2687470034"><span class="h2">Determine transplant eligibility</span><span class="headingEndMark"> — </span>Eligibility for and access to autologous HCT impacts our choice of therapy  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>). When compared with chemotherapy alone, autologous HCT delays progression and improves OS, as discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Benefits of autologous HCT versus chemotherapy alone'</a>.)</p><p>Access to HCT in resource-limited settings is variable, and a lower percentage of patients will be eligible due to diagnostic delays and a higher incidence of advanced disease. (See <a class="local">'Common challenges in the resource-limited setting'</a> above and  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Determine transplant eligibility'</a>.) </p><p>Practical issues regarding the use of autologous HCT in MM are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H1531993623"><span class="h2">Patients eligible for transplant</span></p><p class="headingAnchor" id="H1343274420"><span class="h3">Induction therapy</span><span class="headingEndMark"> — </span>In patients who are candidates for and have access to autologous HCT, induction chemotherapy is administered for three to six cycles prior to stem cell collection in order to reduce the number of tumor cells in the bone marrow and peripheral blood, lesson symptoms, and reverse end-organ damage  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>). </p><p>As in resource-abundant settings, three-drug regimens are preferred over two-drug regimens because randomized trials show that they delay progression and may improve OS. Use of four-drug regimens is evolving, but it is generally cost-prohibitive in the resource-limited setting. </p><p>Our preferred three-drug regimen for HCT-eligible patients in resource-limited settings is influenced by whether there is access to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> is available, we suggest either of the following: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd)  (<a class="graphic graphic_table graphicRef101205" href="/z/d/graphic/101205.html" rel="external">table 4</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, thalidomide, dexamethasone'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, cyclophosphamide, dexamethasone'</a>)</p><p></p><p class="bulletIndent1">VTd is preferred for most patients, except for those with underlying neuropathy. In a multicenter phase 3 trial (IFM2013-04) comparing these two regimens in patients undergoing HCT, VTd resulted in deeper responses and less hematologic toxicity, yet more neurotoxicity [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1">In some resource-limited settings, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> may be available at low cost and approved for use in initial therapy. In such countries, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, lenalidomide, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd) is preferred instead of VTd or VCd, similar to the approach used in resource-abundant settings. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, lenalidomide, dexamethasone'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> is not available or not tolerated, we offer <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (CTd). (See <a class="local">'Cyclophosphamide, thalidomide, and dexamethasone (CTd)'</a> below.)</p><p></p><p>Our preference for a bortezomib-containing regimen, if available, is based on data that suggest that proteasome inhibitors such as <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> may abrogate the prognostic impact of at least some high-risk genetic markers making bortezomib-containing therapies an attractive option regardless of genetic risk. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'High-risk myeloma'</a>.)</p><p>Melphalan-based therapy should<strong> not</strong> be used for patients who plan to undergo HCT. Although <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> is an active drug in MM, it is associated with damage to the hematopoietic stem cell compartment as well as an increased risk of myelodysplasia following transplantation [<a href="#rid10">10-12</a>]. </p><p class="headingAnchor" id="H2139522544"><span class="h3">Timing of HCT</span><span class="headingEndMark"> — </span>In resource-limited settings, we suggest induction therapy followed by early autologous HCT rather than delaying transplant until relapse. This preference places a high value on delaying progression and recognizes the limited availability of stem cell storage and decreased availability of effective treatment options at the time of relapse in resource-limited settings. </p><p>In resource-abundant settings, HCT can be offered as part of initial therapy (early HCT) or delayed until the time of first relapse (delayed transplant). Factors that may impact the choice between early and delayed HCT are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Eligible for autologous transplant'</a>.)</p><p class="headingAnchor" id="H416676476"><span class="h3">Consolidation</span><span class="headingEndMark"> — </span>Patients with a very good partial response (VGPR) or better after HCT proceed to maintenance therapy without consolidation. In such patients, consolidation with additional cycles of the same triplet regimen used for induction is unlikely to offer benefit above that attained with maintenance alone. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Tandem HCT and/or consolidation'</a>.)</p><p>Consolidation may be considered on a case-by-case basis for patients with less than a VGPR after HCT. Limited data suggest that an additional two to four cycles of induction therapy may result in a modest improvement in depth of response, but at a cost of increased toxicity, and no clear OS benefit. </p><p>In a prospective trial of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd) used as induction before and consolidation after double autologous HCT for newly diagnosed MM, VTd consolidation increased the complete response (CR) and near CR rates by 12 and 10 percent, respectively [<a href="#rid13">13</a>]. Among the 82 patients who had not achieved a CR after double HCT, VTd consolidation deepened the response in 45 patients (55 percent) and 25 patients (30 percent) achieved a CR. In the same trial, deeper responses were not seen in those who received consolidation with thalidomide and dexamethasone alone.</p><p>Other trials incorporated an agent not previously used in the consolidation regimen. As an example, in one randomized trial of 370 bortezomib-naïve patients who had undergone autologous HCT, consolidation with a five-month course of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> improved median progression-free survival (PFS; 27 versus 20 months) but not OS [<a href="#rid14">14</a>]. Toxicities included sensorimotor peripheral neuropathy and neuropathic pain. While the induction regimen used was not specified, most patients received <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>.</p><p class="headingAnchor" id="H1875268207"><span class="h3">Maintenance</span><span class="headingEndMark"> — </span>Following autologous HCT, we offer maintenance therapy rather than observation until progression. In resource-limited settings where <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> is not available or affordable, we offer <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> maintenance until progression or unacceptable toxicity. When compared with no maintenance, thalidomide maintenance prolongs PFS by approximately 10 months but is associated with a significant increase in long-term toxicities, including peripheral neuropathy and thromboembolism, leading to thalidomide discontinuation in a substantial number of patients (30 to 80 percent by two years). While some have [<a href="#rid15">15</a>], most trials have not shown an improvement in OS [<a href="#rid16">16-19</a>]. Careful monitoring and dose adjustment for toxicities is critical [<a href="#rid20">20</a>].</p><p>The use of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> maintenance after HCT was analyzed in a 2012 meta-analysis of six randomized trials that included data from 2786 patients who had undergone HCT, with the following findings [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> maintenance improved PFS (hazard ratio [HR] 0.65, 95% CI 0.59-0.72); a benefit seen in trials that used thalidomide during both induction and maintenance and in those that used thalidomide during maintenance alone. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While there was a statistically significant increase in OS (HR 0.84; 95% CI 0.73-0.97) demonstrated, caution must be used in interpreting these results as there was significant heterogeneity among the results of individual trials. This heterogeneity may be due to differences in patient population and in therapies available at relapse. In most studies, a survival benefit is only seen in a subset of patients, such as those who fail to achieve a VGPR with transplant or those with certain cytogenetic abnormalities.</p><p></p><p>In resource-abundant settings, maintenance is routinely given after HCT using drugs with more tolerable side effect profiles (eg, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>). In some resource-limited settings, lenalidomide may be available at low cost and approved for use as maintenance therapy. In such countries, maintenance with lenalidomide is preferred instead of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, similar to the approach used in resource-abundant settings. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Maintenance'</a>.)</p><p class="headingAnchor" id="H1754237552"><span class="h2">Patients not eligible for transplant</span><span class="headingEndMark"> — </span>For patients who are not candidates for or who do not have access to autologous HCT, we offer 8 to 12 cycles of a three-drug regimen followed by observation until progression rather than further chemotherapy  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>). While <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> maintenance prolongs remission, use is limited by toxicity, especially neurotoxicity. </p><p>Our preferred three-drug regimen for these patients is influenced by whether there is access to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> is available, we suggest either of the following: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd)  (<a class="graphic graphic_table graphicRef101205" href="/z/d/graphic/101205.html" rel="external">table 4</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, thalidomide, dexamethasone'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, cyclophosphamide, dexamethasone'</a>)</p><p></p><p class="bulletIndent1">If both are reasonable options for the patient, VTd is preferred as it may be more effective. However, many patients will have comorbidities (eg, diabetes with neuropathy) that may preclude administration of nine cycles of VTd. VCd may be a better choice in such cases. </p><p></p><p class="bulletIndent1">In some resource-limited settings, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> may be available at low cost and approved for use in initial therapy. In such countries, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, lenalidomide, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd) can be used instead of VTd or VCd similar to the approach used in resource-abundant settings (approximately eight cycles of VRd followed by lenalidomide maintenance). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Maintenance for patients who are ineligible for or defer HCT'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> is not available, we suggest either of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (CTd) (see <a class="local">'Cyclophosphamide, thalidomide, and dexamethasone (CTd)'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">Melphalan</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> (MPT)  (<a class="graphic graphic_table graphicRef53179" href="/z/d/graphic/53179.html" rel="external">table 6</a>) (see <a class="local">'Melphalan, prednisone, and thalidomide (MPT)'</a> below)</p><p></p><p class="bulletIndent1">Either regimen is a reasonable choice. A randomized trial comparing these two regimens was closed early due to slow accrual, and small numbers limit interpretation [<a href="#rid22">22</a>]. When compared with MPT, CTd resulted in numerically higher overall response rates (90 versus 68 percent), and a similar median PFS (24 versus 26 months).  </p><p></p><p>The number of cycles used for an individual patient depends on how well they tolerate the regimen and the response to treatment. If the disease continues to respond and the patient is tolerating therapy, we will offer up to 12 cycles of initial therapy.</p><p>The use of <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> has declined in much of the world due to concerns of toxicity (eg, hematopoietic stem cell damage, risk of myelodysplasia) and the availability of other effective regimens. In resource-abundant settings, clinicians have shifted towards initial therapy that incorporates agents such as immunomodulatory drugs (eg, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>), proteasome inhibitors (eg, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>), and monoclonal antibodies (eg, <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p class="headingAnchor" id="H1104768628"><span class="h1">REVIEW OF CHEMOTHERAPY REGIMENS</span><span class="headingEndMark"> — </span>The following sections will present data regarding the administration, efficacy, and toxicity of regimens that may be considered in patients in resource-limited settings largely defined as those areas with limited access to <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> analogs, proteasome inhibitors, monoclonal antibodies, and other novel agents that are commonly used in resource-abundant settings. More modern regimens are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p class="headingAnchor" id="H203530840"><span class="h2">Bortezomib, cyclophosphamide, and dexamethasone (VCd or CyBorD)</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 5</a>) is one or our preferred treatment options for patients who have access to bortezomib, regardless of whether they are candidates for autologous hematopoietic cell transplantation (HCT)  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>). </p><p>VCd is also used in resource-abundant settings to treat patients at higher risk of complications with <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> (eg, acute kidney failure, increased thromboembolic risk). Details on efficacy, toxicity, and administration are described separately. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, cyclophosphamide, dexamethasone'</a>.)</p><p class="headingAnchor" id="H771134835"><span class="h2">Bortezomib, thalidomide, and dexamethasone (VTd)</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd)  (<a class="graphic graphic_table graphicRef101205" href="/z/d/graphic/101205.html" rel="external">table 4</a>) is one or our preferred treatment options for patients who have access to bortezomib, regardless of whether they are candidates for autologous HCT  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>). </p><p>VTd is also used in resource-abundant settings to treat patients presenting with acute kidney failure. Details on efficacy, toxicity, and administration are described separately. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, thalidomide, dexamethasone'</a>.)</p><p class="headingAnchor" id="H3790446486"><span class="h2">Cyclophosphamide, thalidomide, and dexamethasone (CTd)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – The all-oral combination of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (CTd) is one of our preferred regimens for patients who do not have access to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>). It can be used as induction therapy prior to stem cell collection and autologous HCT or at attenuated doses as initial therapy for patients who are not candidates for HCT. </p><p></p><p class="bulletIndent1">Further details on class-specific toxicities and ways to mitigate them are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Immunomodulatory drugs'</a> and  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Corticosteroids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCT-eligible patients</strong> – A multicenter randomized trial (MRC Myeloma IX) compared CTd versus CVAD (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>) in 1111 HCT-eligible patients with newly diagnosed MM [<a href="#rid23">23</a>].  </p><p></p><p class="bulletIndent1">CTd was given as up to six 21-day cycles of oral <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (500 mg per week), <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> (100 mg per day increasing to 200 mg per day if tolerated), and oral <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (40 mg per day on days 1 to 4 and 12 to 15). Prophylaxis for venous thromboembolism (VTE) was at the discretion of the clinician and not specified in the protocol. HCT was performed in 67 percent.</p><p></p><p class="bulletIndent1">CTd resulted in higher rates of overall response (83 versus 71 percent), complete response (13 versus 8 percent), and overall response post-transplant (50 versus 37 percent). After a median follow-up of 47 months, the two arms had similar rates of progression-free survival (PFS; median 27 versus 25 months) and overall survival (OS).  </p><p></p><p class="bulletIndent1">Among those assigned to CTd, 29 percent required <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> dose reduction. When compared with CVAD, CTd resulted in less grade 3 or 4 cytopenias (5 versus 12 percent) and infection (12 versus 21 percent), more grade 3 or 4 constipation (3.6 versus 1.5 percent) and somnolence (3.0 versus 1.3 percent), and similar rates of kidney impairment (3.6 versus 3.2 percent), thromboembolic events (16 versus 18 percent), and early mortality (7 versus 9 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCT-ineligible patients</strong> – The MRC Myeloma IX trial included a second cohort of 849 patients with newly diagnosed MM ineligible for HCT who were randomly assigned to receive an attenuated regimen of CTd versus <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (MP) [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1">Attenuated CTd was given as up to nine 28-day cycles of oral <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (500 mg per week), <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> (50 mg per day, increasing every four weeks in 50 mg increments to a maximum of 200 mg per day), and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (20 mg/day on days 1 to 4 and 15 to 18). </p><p></p><p class="bulletIndent1">CTd resulted in higher rates of overall response (64 versus 33 percent), complete response (13 versus 2 percent), and very good partial response (17 versus 2 percent). After a median follow-up of 44 months, the two arms had similar rates of PFS (median 13 versus 12 months) and OS (median 33 versus 31 months). Six percent of patients in each arm died within 60 days of randomization. There were two deaths in each group due to thromboembolism.</p><p></p><p class="bulletIndent1">Among those assigned to CTd, 31 percent required <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> dose reduction. When compared with MP, CTd resulted in more all-grade thromboembolic events (16 versus 5 percent), sensory neuropathy (24 versus 6 percent), motor neuropathy (12 versus 3 percent), constipation (41 versus 18 percent), and rash (15 versus 7 percent). </p><p></p><p class="headingAnchor" id="H757255070"><span class="h2">Melphalan, prednisone, and thalidomide (MPT)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – The combination of <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> (MPT) is a preferred highly active treatment option for initial therapy in patients with standard-risk MM who are not candidates for HCT in resource-limited settings  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef53179" href="/z/d/graphic/53179.html" rel="external">table 6</a>). </p><p></p><p class="bulletIndent1">Further details on class-specific toxicities of immunomodulatory drugs and corticosteroids and ways to mitigate them are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Immunomodulatory drugs'</a> and  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Corticosteroids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Although it has been given at other doses and schedules, the MPT regimen we use is illustrated in the table  (<a class="graphic graphic_table graphicRef53179" href="/z/d/graphic/53179.html" rel="external">table 6</a>). Initial dose reductions to minimize toxicity are suggested for older adults (age 75 and older) and those with comorbidities or frailty [<a href="#rid25">25</a>]. Thus, when using MPT in older or frail patients, we lower the dose of <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> to 0.2 mg/kg, and use <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> at a dose not exceeding 100 mg per day [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1">The MPT regimen requires routine thromboprophylaxis in all patients [<a href="#rid27">27</a>]. Options for prophylaxis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism", section on 'Thalidomide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicities</strong> – Severe (grade 3/4) toxicities associated with MPT include neutropenia (23 to 48 percent), thrombosis or embolism (12 percent), constipation (10 percent), and somnolence/fatigue/dizziness (8 percent) [<a href="#rid26">26,28,29</a>]. MPT is also associated with high rates of all stages of peripheral neuropathy (39 percent) and depression (7 percent).</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> should be discontinued or dose reduced when paresthesias are accompanied by moderate to severe pain or motor deficit, or when they interfere with activities of daily living [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – When compared with MP, MPT is associated with improved PFS and OS, but it results in greater toxicity.</p><p></p><p class="bulletIndent1">MPT has been compared with MP in several large randomized trials. Two large meta-analyses based on these trials confirmed an improvement in response rate with the addition of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid31">31,32</a>]. Furthermore, the addition of thalidomide to MP was associated with a significant improvement in PFS (hazard ratio [HR] 0.68, 95% CI 0.56-0.81) and OS (HR 0.81; 95% CI 0.70-0.94) [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H1293938103"><span class="h2">Bortezomib, melphalan, prednisone, and thalidomide (VMPT)</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> (VMPT) is an experimental four-drug regimen. </p><p>A prospective cooperative group trial of 511 patients older than 65 years with newly diagnosed MM randomly assigned therapy with VMPT or VMP [<a href="#rid33">33,34</a>]. After nine cycles, the patients assigned to VMPT received maintenance therapy with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>; those given VMP did not receive maintenance. After an early protocol amendment, bortezomib was given on a weekly schedule, rather than twice weekly, during all induction cycles on both treatment arms.</p><p>After a median follow-up of 54 months, VMPT (followed by maintenance therapy) improved PFS (median 35 versus 25 months, HR 0.58) and OS (61 versus 51 percent at five years; HR 0.70) [<a href="#rid35">35</a>]. VMPT was associated with a higher rate of severe (grade 3 or 4) toxicity, which included neutropenia (38 percent), thrombocytopenia (22 percent), peripheral neuropathy (11 percent), and cardiologic events (11 percent).</p><p>VMPT has not been compared with other regimens that incorporate novel agents. Further, it is not clear whether the survival benefit is due to the addition of the fourth drug to the induction regimen, or due to the addition of maintenance. </p><p class="headingAnchor" id="H11"><span class="h1">MONITORING DISEASE RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy  (<a class="graphic graphic_table graphicRef55362" href="/z/d/graphic/55362.html" rel="external">table 7</a>). The preferred method is the measurement of monoclonal (M) protein in serum or urine, although responses can be assessed earlier by serum free light chain (FLC) measurements. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment"</a>.)</p><p class="headingAnchor" id="H2743658572"><span class="h1">RELAPSED OR REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>Most patients with MM will have an initial response to treatment. However, conventional therapy is not curative and MM will ultimately relapse. In addition, a minority will have primary refractory disease that does not respond to initial treatment.</p><p>Treatment of relapsed or refractory MM is highly individualized and depends on patient factors and access to therapies. Accompanying tables provide active drugs by class  (<a class="graphic graphic_table graphicRef121137" href="/z/d/graphic/121137.html" rel="external">table 8</a>) and major toxicities of selected treatment regimens  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 9</a>). </p><p>Choice among available options is impacted by prior therapy, response and tolerability, and comorbidities. </p><p>The following general principles help guide care:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are eligible and have access to autologous hematopoietic cell transplantation (HCT) may be candidates for a first or second HCT. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Second autologous HCT after relapse'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Response durations more than the median for a given therapy represents a good response (eg, &gt;12 months after initial treatment with CTd alone or &gt;24 months after initial treatment with CTd plus HCT); repeat treatment with the same therapy may result in a response of equal or shorter duration. This approach aims to derive maximum benefit from available agents prior to switching regimens.   </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression on or within 60 days of receiving standard doses of a specific therapy defines disease that is refractory to that agent. Retreatment is not likely to be effective and other agents should be used. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients are strongly encouraged to participate in , where available. This may provide access to otherwise unavailable agents.</p><p></p><p>Additional information about novel agents, combinations, and modalities used in resource-abundant settings is provided separately. (See  <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse"</a> and  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse"</a>.)</p><p class="headingAnchor" id="H465250937"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/688.html" rel="external">"Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/690.html" rel="external">"Patient education: Multiple myeloma treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common challenges</strong> – In resource-limited settings, patients with multiple myeloma (MM) have limited access to <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> analogs, proteasome inhibitors, monoclonal antibodies, and other novel agents. Additional challenges include heterogenous access to care, diagnostic delays, access to molecular studies, and logistical support. (See <a class="local">'Common challenges in the resource-limited setting'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation and diagnosis</strong> – Patients in resource-limited settings are more likely to have advanced disease at diagnosis. While the evaluation of suspected cases may differ based on available resources  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>), the diagnosis uses International Myeloma Working Group criteria  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>). (See <a class="local">'Clinical presentation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy and preventative measures</strong> – Treatment is not curative. It alleviates symptoms, reverses cytopenias, and decreases end-organ damage, and it aims to improve quality of life and prolong overall survival. (See <a class="local">'Goals of therapy'</a> above.)</p><p></p><p class="bulletIndent1">Preventative measures are key to reducing the incidence of skeletal events, kidney damage, infections, neuropathy, and thrombosis. (See <a class="local">'Prevention and management of complications'</a> above.)</p><p></p><p class="bulletIndent1">Myeloma-directed therapies are individualized based on access to drugs/modalities and patient comorbidities. There is no standard of care. Our preferred approach depends on the feasibility of autologous hematopoietic cell transplantation (HCT) and access to <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>  (<a class="graphic graphic_algorithm graphicRef139946" href="/z/d/graphic/139946.html" rel="external">algorithm 4</a>). These treatments are effective in standard- and high-risk disease, making them attractive options in the absence of molecular studies for risk stratification. (See <a class="local">'Initial treatment'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients eligible for HCT</strong> – In patients who are candidates for and have access to HCT, we suggest three to six cycles of induction therapy followed by early autologous HCT rather than delaying transplant until relapse (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Timing of HCT'</a> above.)</p><p></p><p class="bulletIndent1">If available, we suggest a bortezomib-containing regimen rather than others (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>); options include (see <a class="local">'Induction therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd)  (<a class="graphic graphic_table graphicRef101205" href="/z/d/graphic/101205.html" rel="external">table 4</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, thalidomide, dexamethasone'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, cyclophosphamide, dexamethasone'</a>)</p><p></p><p class="bulletIndent1">If the patient has access to both <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, then bortezomib, lenalidomide, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd) is preferred instead of VTd or VCd, similar to the approach used in resource-abundant settings. </p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> is not available or not tolerated, we offer <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (CTd). Melphalan-based therapy should<strong> not</strong> be used for patients who plan to undergo HCT. (See <a class="local">'Cyclophosphamide, thalidomide, and dexamethasone (CTd)'</a> above.)</p><p></p><p class="bulletIndent1">Following autologous HCT, we suggest <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> maintenance rather than observation (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Maintenance delays progression by approximately 10 months, but it is associated with risks of neuropathy and thrombosis and does not improve overall survival for most patients. If the patient has access to <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, lenalidomide maintenance is preferred over thalidomide maintenance. (See <a class="local">'Maintenance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients not eligible for HCT</strong> – For patients who are not candidates for or who do not have access to autologous HCT, we offer 8 to 12 cycles of induction, as tolerated. Afterwards, we suggest observation until progression rather than further chemotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> maintenance prolongs remission, use is limited by toxicity, especially neurotoxicity. </p><p></p><p class="bulletIndent1">If available, we suggest a bortezomib-containing three-drug regimen rather than a regimen that does not contain <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>); options include (see <a class="local">'Patients not eligible for transplant'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VTd)  (<a class="graphic graphic_table graphicRef101205" href="/z/d/graphic/101205.html" rel="external">table 4</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, thalidomide, dexamethasone'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VCd, also called CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Bortezomib, cyclophosphamide, dexamethasone'</a>)</p><p></p><p class="bulletIndent1">If the patient has access to both <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, then bortezomib, lenalidomide, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (VRd) followed by lenalidomide maintenance is preferred over VTd or VCd, similar to the approach used in resource-abundant settings. </p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> is not available, we offer one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (CTd) (see <a class="local">'Cyclophosphamide, thalidomide, and dexamethasone (CTd)'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">Melphalan</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> (MPT)  (<a class="graphic graphic_table graphicRef53179" href="/z/d/graphic/53179.html" rel="external">table 6</a>) (see <a class="local">'Melphalan, prednisone, and thalidomide (MPT)'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – We evaluate response to therapy before each treatment cycle  (<a class="graphic graphic_table graphicRef55362" href="/z/d/graphic/55362.html" rel="external">table 7</a>) based on monoclonal protein in serum and urine and free light chain measurements. (See  <a class="medical medical_review" href="/z/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed or refractory disease</strong> – Treatment of relapsed or refractory MM is highly individualized based on patient factors and access to therapies. Accompanying tables provide active drugs by class  (<a class="graphic graphic_table graphicRef121137" href="/z/d/graphic/121137.html" rel="external">table 8</a>) and major toxicities of selected treatment regimens  (<a class="graphic graphic_table graphicRef108257" href="/z/d/graphic/108257.html" rel="external">table 9</a>). </p><p></p><p class="bulletIndent1">Choice is impacted by prior therapy, response and tolerability, and comorbidities. (See <a class="local">'Relapsed or refractory disease'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, et al. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. Clin Lymphoma Myeloma Leuk 2019; 19:e43.</a></li><li><a class="nounderline abstract_t">Tarín-Arzaga L, Arredondo-Campos D, Martínez-Pacheco V, et al. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. Cancer 2018; 124:1946.</a></li><li><a class="nounderline abstract_t">Curado MP, Oliveira MM, Silva DRM, Souza DLB. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med 2018; 7:2101.</a></li><li><a class="nounderline abstract_t">de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016. Br J Haematol 2020; 188:383.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538.</a></li><li><a class="nounderline abstract_t">OSGOOD EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960; 9:1.</a></li><li><a class="nounderline abstract_t">Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208:1680.</a></li><li><a class="nounderline abstract_t">Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113.</a></li><li><a class="nounderline abstract_t">Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 2016; 127:2569.</a></li><li><a class="nounderline abstract_t">Boccadoro M, Palumbo A, Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87:846.</a></li><li><a class="nounderline abstract_t">Goldschmidt H, Hegenbart U, Wallmeier M, et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98:736.</a></li><li><a class="nounderline abstract_t">Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (&gt;/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120:413.</a></li><li><a class="nounderline abstract_t">Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120:9.</a></li><li><a class="nounderline abstract_t">Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013; 121:4647.</a></li><li><a class="nounderline abstract_t">Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27:1788.</a></li><li><a class="nounderline abstract_t">Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289.</a></li><li><a class="nounderline abstract_t">Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012; 119:7.</a></li><li><a class="nounderline abstract_t">Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021.</a></li><li><a class="nounderline abstract_t">Ludwig H, Adam Z, Tóthová E, et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010; 95:1548.</a></li><li><a class="nounderline abstract_t">van de Donk NW, van der Holt B, Minnema MC, et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol 2018; 5:e479.</a></li><li><a class="nounderline abstract_t">Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119:3003.</a></li><li><a class="nounderline abstract_t">Hungria VT, Crusoé EQ, Maiolino A, et al. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Ann Hematol 2016; 95:271.</a></li><li><a class="nounderline abstract_t">Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012; 97:442.</a></li><li><a class="nounderline abstract_t">Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011; 118:1231.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118:4519.</a></li><li><a class="nounderline abstract_t">Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664.</a></li><li><a class="nounderline abstract_t">Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414.</a></li><li><a class="nounderline abstract_t">Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209.</a></li><li><a class="nounderline abstract_t">Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica 2013; 98:87.</a></li><li><a class="nounderline abstract_t">Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111:3968.</a></li><li><a class="nounderline abstract_t">Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 2011; 25:689.</a></li><li><a class="nounderline abstract_t">Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011; 118:1239.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; 28:5101.</a></li><li><a class="nounderline abstract_t">Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014; 32:634.</a></li></ol></div><div id="topicVersionRevision">Topic 6650 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30297171" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461639" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29573332" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of multiple myeloma in 17 Latin American countries: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31392724" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439696" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13731417" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The survival time of patients with plasmocytic myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5818682" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754936" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002117" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161361" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332333" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580955" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mobilization of CD34+ cells in elderly patients (&gt;/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22498745" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23616624" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273705" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16873668" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021371" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16525139" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thalidomide and hematopoietic-cell transplantation for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20418244" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30290905" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271445" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : IMWG consensus on maintenance therapy in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26518211" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22058209" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21652683" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21841166" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451428" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094721" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17920916" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22875621" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18245666" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Thalidomide for treatment of multiple myeloma: 10 years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233832" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670471" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940200" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807892" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449241" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
